Game-Changer for Asymptomatic Alzheimer's Trials?
email article Blood tests to screen for amyloid-beta could cut the need for PET scans in half in asymptomatic Alzheimer's research trials, a British cohort study suggested. To find 100 amyloid PET-positive, dementia-free older adults from a population with similar amyloid PET positivity prevalence to the study cohort without plasma screening, 543 PET scans would need to be performed, said Jonathan Schott, MD, of University College London in England, and co-authors. Using mass spectrometry measures of plasma amyloid-beta would require 623 people to have a blood test, and of those, 243 wo...